BRPI0518228B8 - inibidores de cinesina mitótica e uso dos mesmos - Google Patents

inibidores de cinesina mitótica e uso dos mesmos

Info

Publication number
BRPI0518228B8
BRPI0518228B8 BRPI0518228A BRPI0518228A BRPI0518228B8 BR PI0518228 B8 BRPI0518228 B8 BR PI0518228B8 BR PI0518228 A BRPI0518228 A BR PI0518228A BR PI0518228 A BRPI0518228 A BR PI0518228A BR PI0518228 B8 BRPI0518228 B8 BR PI0518228B8
Authority
BR
Brazil
Prior art keywords
inhibitors
mitotic kinesin
kinesin inhibitors
methods
pharmaceutical compositions
Prior art date
Application number
BRPI0518228A
Other languages
English (en)
Inventor
M Wallace Eli
Laird Ellen
Hans Jeremy
Robinson John
P Lyssikatos Joseph
Zhao Qian
Allen Shelley
Aicher Tom
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of BRPI0518228A publication Critical patent/BRPI0518228A/pt
Publication of BRPI0518228B1 publication Critical patent/BRPI0518228B1/pt
Publication of BRPI0518228B8 publication Critical patent/BRPI0518228B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/201—Esters of thiophosphorus acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • C07F9/65392—Five-membered rings containing two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides

Abstract

inibidores de cinesina mitótica e métodos de uso destes. a presente invenção refere-se a inibidores de cinesinas mitóticas, particularmente ksp, e métodos para produzir estes inibidores. a invenção também fornece composições farmacêuticas que compreendem os inibidores da invenção e métodos de utilização dos inibidores e composições farmacêuticas no tratamento e prevenção de vários distúrbios.
BRPI0518228A 2004-10-19 2005-10-18 inibidores de cinesina mitótica e uso dos mesmos BRPI0518228B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US62004804P 2004-10-19 2004-10-19
US60/620,048 2004-10-19
US11/252,232 2005-10-17
US11/252,232 US7449486B2 (en) 2004-10-19 2005-10-17 Mitotic kinesin inhibitors and methods of use thereof
PCT/US2005/037305 WO2006044825A2 (en) 2004-10-19 2005-10-18 Mitotic kinesin inhibitors and methods of use thereof

Publications (3)

Publication Number Publication Date
BRPI0518228A BRPI0518228A (pt) 2008-11-04
BRPI0518228B1 BRPI0518228B1 (pt) 2020-10-20
BRPI0518228B8 true BRPI0518228B8 (pt) 2021-05-25

Family

ID=36203637

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518228A BRPI0518228B8 (pt) 2004-10-19 2005-10-18 inibidores de cinesina mitótica e uso dos mesmos

Country Status (27)

Country Link
US (8) US7449486B2 (pt)
EP (1) EP1809280B1 (pt)
JP (4) JP5128283B2 (pt)
KR (1) KR101280755B1 (pt)
CN (4) CN103626720B (pt)
AT (1) ATE523196T1 (pt)
AU (1) AU2005295403B2 (pt)
BR (1) BRPI0518228B8 (pt)
CA (4) CA2952920A1 (pt)
CY (1) CY1112238T1 (pt)
DK (1) DK1809280T3 (pt)
ES (1) ES2370774T3 (pt)
HK (1) HK1106131A1 (pt)
HR (1) HRP20110764T1 (pt)
IL (2) IL182417A0 (pt)
ME (1) ME01950B (pt)
MX (1) MX2007004547A (pt)
NO (1) NO341725B1 (pt)
NZ (1) NZ554306A (pt)
PL (1) PL1809280T3 (pt)
PT (1) PT1809280E (pt)
RS (1) RS52037B (pt)
RU (1) RU2426729C2 (pt)
SI (1) SI1809280T1 (pt)
TW (1) TWI357900B (pt)
WO (1) WO2006044825A2 (pt)
ZA (1) ZA200703168B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE513821T1 (de) * 2001-12-11 2011-07-15 Kyowa Hakko Kirin Co Ltd Thiadiazolin-derivate zur behandlung von krebs
EP2327702B1 (en) 2003-04-18 2012-08-29 Kyowa Hakko Kirin Co., Ltd. Mitotic kinesin inhibitor
KR20060014071A (ko) * 2003-06-10 2006-02-14 교와 핫꼬 고교 가부시끼가이샤 티아디아졸린 유도체
CN101005837A (zh) * 2004-08-18 2007-07-25 默克公司 有丝分裂驱动蛋白抑制剂
US7449486B2 (en) 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
CA2602397A1 (en) * 2005-03-22 2006-09-28 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for solid tumor
TW200720265A (en) * 2005-03-22 2007-06-01 Kyowa Hakko Kogyo Kk Agent for treatment of hematopoietic tumor
UA95907C2 (en) * 2005-05-02 2011-09-26 Эррей Биофарма Инк. Mitotic kinesin inhibitors and methods of use thereof
JPWO2006137490A1 (ja) * 2005-06-24 2009-01-22 協和発酵キリン株式会社 再狭窄治療剤
US8324257B2 (en) * 2006-10-03 2012-12-04 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
WO2008070739A1 (en) * 2006-12-06 2008-06-12 Cytokinetics, Inc. Ksp activators
EP2220061B1 (en) * 2007-10-19 2016-02-17 Merck Sharp & Dohme Corp. Spiro-condensed 1, 3, 4-thiadiazole derivatives for inhibiting ksp kinesin activity
JP2011503076A (ja) * 2007-11-09 2011-01-27 シェーリング コーポレイション Ｋｓｐキネシン活性を阻害するための化合物
EP2349259B1 (en) * 2008-10-16 2015-12-23 Array Biopharma, Inc. Inhibitors of mitosis for increasing apoptosis in therapy
US9561214B2 (en) * 2008-10-16 2017-02-07 Array Biopharma Inc. Method of treatment using inhibitors of mitosis
WO2010132520A1 (en) * 2009-05-13 2010-11-18 Schering Corporation Spiro 1,3,4-thiadiazoline derivatives as ksp inhibitors
ES2742195T3 (es) 2010-03-12 2020-02-13 Omeros Corp Inhibidores de PDE10 y composiciones y métodos relacionados
FR2991199B1 (fr) * 2012-05-30 2015-05-15 IFP Energies Nouvelles Procede de preparation d'un catalyseur mettant en oeuvre une etape de sechage rapide et son utilisation pour la synthese fischer-tropsch
WO2014028543A1 (en) 2012-08-13 2014-02-20 Array Biopharma Inc. Arry-520 for use in treating cancer in a patient with low aag
WO2015021324A1 (en) 2013-08-08 2015-02-12 Array Biopharma Inc. Filanesib combined with pomalidomide displays enhanced anti-tumor activity
BR112016014830A2 (pt) 2013-12-23 2017-09-19 Bayer Pharma AG Conjugados de fármaco de anticorpo (adcs) com inibidores de ksp
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ630803A (en) 2014-04-28 2016-03-31 Omeros Corp Optically active pde10 inhibitor
JP6743015B2 (ja) 2014-12-15 2020-08-19 バイエル ファーマ アクチエンゲゼルシャフト Ｋｓｐ阻害剤の脱グリコシル化抗ｔｗｅａｋｒ抗体との抗体薬物複合体（ａｄｃ類）
KR20170139074A (ko) 2015-04-24 2017-12-18 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법
CN114917361A (zh) 2015-06-22 2022-08-19 拜耳医药股份有限公司 具有酶可裂解基团的抗体药物缀合物（adc）和抗体前药缀合物（apdc）
MX2017017138A (es) * 2015-06-23 2018-04-30 Bayer Pharma AG Conjugados homogeneos especificos de sitio con inhibidores de ksp.
CA2990394A1 (en) 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-tweakr-antibodies
US11071788B2 (en) 2015-06-23 2021-07-27 Bayer Pharma Aktiengesellschaft Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies
CA3003611C (en) 2015-11-04 2022-11-01 Omeros Corporation Solid state forms of a pde10 inhibitor
EP3919518A1 (en) 2016-06-15 2021-12-08 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
EP3558388A1 (de) 2016-12-21 2019-10-30 Bayer Pharma Aktiengesellschaft Binder-wirkstoff-konjugate (adcs) mit enzymatisch spaltbaren gruppen
EP3558387B1 (de) 2016-12-21 2021-10-20 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
CA3103327A1 (en) 2018-06-18 2019-12-26 Bayer Aktiengesellschaft Binder/active agent conjugates directed against cxcr5, having enzymatically cleavable linkers and improved activity profile

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2702803A (en) * 1954-04-12 1955-02-22 Lilly Co Eli Substituted heterodiazoles
ATE72431T1 (de) * 1985-08-31 1992-02-15 Fisons Plc 5-gliedrige heterocyclische angiotensinumwandlungsenzym-inhibitoren.
US4762072A (en) * 1986-10-07 1988-08-09 Westinghouse Electric Corp. Desk and space dividing wall panel assembly
GB8625774D0 (en) 1986-10-28 1986-12-03 Reckitt & Colmann Prod Ltd Thiadiazole derivative
JPH0572686A (ja) 1991-09-11 1993-03-26 Konica Corp ハロゲン化銀写真感光材料
WO1993022311A1 (en) 1992-04-27 1993-11-11 E.I. Du Pont De Nemours And Company Fungicidal 1,3,4-oxadiazines and 1,3,4-thiadiazines
US6159938A (en) * 1994-11-21 2000-12-12 Cortech, Inc. Serine protease inhibitors comprising α-keto heterocycles
EP0807104A2 (en) * 1995-02-02 1997-11-19 Smithkline Beecham Plc Heterocyclic compounds possessing 5ht 2c? receptor antagonist activity
US5958957A (en) * 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
US5668159A (en) * 1996-05-08 1997-09-16 The Dupont Merck Pharmaceutical Company 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as IIb/IIIa antagonists
AR011164A1 (es) 1997-02-28 2000-08-02 Lilly Co Eli Compuestos heterociclicos, composiciones farmaceuticas que los comprenden, y metodos para inhibir la liberacion del peptido beta-amiloide y/o su sintesismediante el uso de dichos compuestos
BR9813656A (pt) * 1997-12-16 2000-10-10 Warner Lambert Co Aminas como agentes farmacêuticos
JP2000159756A (ja) 1998-11-23 2000-06-13 American Cyanamid Co ２―アリ―ル―δ２―１，３，４―（オキサおよびチア）ジアゾリン殺虫および殺ダニ剤
US6235762B1 (en) * 1998-11-23 2001-05-22 American Cyanamid Company 2-aryl-Δ2-1,3,4-(oxa and thia)diazoline insecticidal and acaricidal agents
SK9822001A3 (en) * 1999-01-13 2002-08-06 Warner Lambert Co 1-heterocycle substituted diarylamines, pharmaceutical compositions based thereon and their use in therapy
US6380187B2 (en) * 1999-03-25 2002-04-30 Dingwei Tim Yu Class of thiomorpholino substituted thiazoles
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
WO2001056994A1 (en) 2000-02-04 2001-08-09 Biogen, Inc. Integrin antagonists
WO2003018008A1 (fr) * 2000-02-25 2003-03-06 Shionogi & Co., Ltd. Agent d'accélération de l'expression de apo ai
ATE513821T1 (de) * 2001-12-11 2011-07-15 Kyowa Hakko Kirin Co Ltd Thiadiazolin-derivate zur behandlung von krebs
DE60329990D1 (de) * 2002-03-08 2009-12-24 Merck & Co Inc Mitotische kinesin-hemmer
AU2003246551A1 (en) 2002-06-25 2004-01-06 Dieter Borner Assembly for recording the use of rds radio receivers
US7294643B2 (en) * 2002-11-22 2007-11-13 Board Of Regents, The University Of Texas System UK-1 analogues: methods of preparation and use
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
US20040167188A1 (en) * 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
EP2327702B1 (en) 2003-04-18 2012-08-29 Kyowa Hakko Kirin Co., Ltd. Mitotic kinesin inhibitor
US7115642B2 (en) * 2003-05-02 2006-10-03 Rigel Pharmaceuticals, Inc. Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating HCV infection
US7326790B2 (en) * 2003-05-02 2008-02-05 Rigel Pharmaceuticals, Inc. Diphenylisoxazole compounds and hydro isomers thereof
WO2004110351A2 (en) * 2003-05-14 2004-12-23 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis c virus
JP4847868B2 (ja) * 2003-05-14 2011-12-28 ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド 化合物、及び、アミロイドベータの調節におけるその使用
US7220745B2 (en) 2003-05-15 2007-05-22 Rigel Pharmaceuticals Heterocyclic compounds useful to treat HCV
US20050009877A1 (en) * 2003-05-15 2005-01-13 Henry Lu Methods of identifying HCV NS5B polymerase inhibitors and their uses
KR20060014071A (ko) * 2003-06-10 2006-02-14 교와 핫꼬 고교 가부시끼가이샤 티아디아졸린 유도체
JPWO2004111023A1 (ja) 2003-06-10 2006-07-27 協和醗酵工業株式会社 チアジアゾリン−１−オキシド誘導体
WO2005035512A1 (ja) 2003-10-10 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. チアジアゾリン誘導体
JP2005232016A (ja) 2004-02-17 2005-09-02 Kyowa Hakko Kogyo Co Ltd オキサジアゾリン誘導体
GB0406867D0 (en) 2004-03-26 2004-04-28 F2G Ltd Antifungal agents
CN101005837A (zh) * 2004-08-18 2007-07-25 默克公司 有丝分裂驱动蛋白抑制剂
US7449486B2 (en) 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
FR2876586B1 (fr) 2004-10-20 2007-10-12 Persee Medica Composition pour prevenir ou traiter le stress, notamment les bouffees de stress chronique et permanent
JP2006265107A (ja) * 2005-03-22 2006-10-05 Kyowa Hakko Kogyo Co Ltd 緑内障治療剤
TW200720265A (en) * 2005-03-22 2007-06-01 Kyowa Hakko Kogyo Kk Agent for treatment of hematopoietic tumor
JP2008150291A (ja) * 2005-03-22 2008-07-03 Kyowa Hakko Kogyo Co Ltd 乾癬治療剤
CA2602397A1 (en) * 2005-03-22 2006-09-28 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for solid tumor
JP2008137893A (ja) * 2005-03-22 2008-06-19 Kyowa Hakko Kogyo Co Ltd 関節炎治療剤
UA95907C2 (en) 2005-05-02 2011-09-26 Эррей Биофарма Инк. Mitotic kinesin inhibitors and methods of use thereof
JPWO2006137490A1 (ja) * 2005-06-24 2009-01-22 協和発酵キリン株式会社 再狭窄治療剤
US8324257B2 (en) 2006-10-03 2012-12-04 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
TWI411395B (zh) 2007-12-24 2013-10-11 Syngenta Participations Ag 殺蟲化合物
US9561214B2 (en) 2008-10-16 2017-02-07 Array Biopharma Inc. Method of treatment using inhibitors of mitosis
WO2014028543A1 (en) 2012-08-13 2014-02-20 Array Biopharma Inc. Arry-520 for use in treating cancer in a patient with low aag
WO2015021324A1 (en) 2013-08-08 2015-02-12 Array Biopharma Inc. Filanesib combined with pomalidomide displays enhanced anti-tumor activity

Also Published As

Publication number Publication date
CN101083988A (zh) 2007-12-05
US9499503B2 (en) 2016-11-22
WO2006044825A3 (en) 2006-10-05
BRPI0518228B1 (pt) 2020-10-20
IL182417A0 (en) 2007-07-24
US8236825B2 (en) 2012-08-07
RU2007118632A (ru) 2008-11-27
TWI357900B (en) 2012-02-11
US20120270803A1 (en) 2012-10-25
PL1809280T3 (pl) 2011-12-30
CN103951633A (zh) 2014-07-30
CA2584866C (en) 2014-09-23
CA2952920A1 (en) 2006-04-27
JP5757666B2 (ja) 2015-07-29
US10017482B2 (en) 2018-07-10
US9102639B2 (en) 2015-08-11
US7956073B2 (en) 2011-06-07
JP2012233012A (ja) 2012-11-29
US20150210658A1 (en) 2015-07-30
ME01950B (me) 2012-04-30
ATE523196T1 (de) 2011-09-15
CN103626720B (zh) 2016-11-16
CN103626720A (zh) 2014-03-12
CA2868912C (en) 2017-01-03
US7449486B2 (en) 2008-11-11
WO2006044825A2 (en) 2006-04-27
US20140094603A1 (en) 2014-04-03
ZA200703168B (en) 2008-06-25
NZ554306A (en) 2010-12-24
TW200621736A (en) 2006-07-01
US20060100161A1 (en) 2006-05-11
CA2584866A1 (en) 2006-04-27
NO20072558L (no) 2007-07-18
NO341725B1 (no) 2018-01-08
CN102532051A (zh) 2012-07-04
BRPI0518228A (pt) 2008-11-04
MX2007004547A (es) 2007-06-07
DK1809280T3 (da) 2011-10-31
KR101280755B1 (ko) 2013-07-08
JP2015129191A (ja) 2015-07-16
CA2852516C (en) 2015-06-02
EP1809280A2 (en) 2007-07-25
HK1106131A1 (en) 2008-03-07
CY1112238T1 (el) 2015-12-09
JP5128283B2 (ja) 2013-01-23
CA2868912A1 (en) 2006-04-27
RU2426729C2 (ru) 2011-08-20
ES2370774T3 (es) 2011-12-22
JP2008516982A (ja) 2008-05-22
JP2014139249A (ja) 2014-07-31
AU2005295403B2 (en) 2011-05-19
AU2005295403A1 (en) 2006-04-27
US20080182992A1 (en) 2008-07-31
CA2852516A1 (en) 2006-04-27
EP1809280A4 (en) 2009-10-21
EP1809280B1 (en) 2011-09-07
US20170066733A1 (en) 2017-03-09
IL219857A0 (en) 2012-06-28
SI1809280T1 (sl) 2011-11-30
JP5911909B2 (ja) 2016-04-27
RS52037B (en) 2012-04-30
US8623895B2 (en) 2014-01-07
US20110201651A1 (en) 2011-08-18
KR20070084348A (ko) 2007-08-24
HRP20110764T1 (hr) 2011-12-31
CN103951633B (zh) 2017-05-10
US20180334441A1 (en) 2018-11-22
PT1809280E (pt) 2011-11-15

Similar Documents

Publication Publication Date Title
BRPI0518228B8 (pt) inibidores de cinesina mitótica e uso dos mesmos
TW200510416A (en) P38 inhibitors and methods of use thereof
WO2004078116A3 (en) P38 inhibitors and methods of use thereof
TW200716153A (en) Mitotic kinesin inhibitors and methods of use thereof
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
TW200604168A (en) Azaindoles useful as inhibitors of rock and other protein kinases
TW200612905A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MY147767A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
TW200621745A (en) Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
BRPI0511124A (pt) pró-drogas de inibidores de erk proteìna cinase de pirrolilpirimidina
DE602004024374D1 (de) Zusammensetzungen zur verwendung als protein-kinase-inhibitoren
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
TW200716561A (en) P38 inhibitors and methods of use thereof
WO2008042928A3 (en) Oxadiazole and thiadiazole derivatives as mitotic kinesin inhibitors and methods of use thereof
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors
UA98926C2 (ru) Ингибитор митотических кинезинов и его использование

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/10/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF